Apple
AAPL
Taylor Morrison Home
TMHC
D.R. Horton
DHI
Petroleo Brasileiro SA Petrobras
PBR
Vale SA
VALE
US Stock MarketDetailed Quotes
ATNM Actinium
- 1.890
- +0.020+1.07%
Close Mar 27 16:00 ET
- 1.900
- +0.010+0.53%
Post 19:51 ET
58.96MMarket Cap-1.36P/E (TTM)
2.010High1.660Low1.53MVolume1.980Open1.870Pre Close2.82MTurnover4.94%Turnover RatioLossP/E (Static)31.20MShares10.24052wk High1.54P/B58.66MFloat Cap1.02952wk Low--Dividend TTM31.04MShs Float450.000Historical High--Div YieldTTM18.71%Amplitude1.029Historical Low1.839Avg Price1Lot Size
Actinium Stock Forum
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...
29
8
$Actinium (ATNM.US)$
Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Thursday, 27th March at 8:45 am
- 99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models
- ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in healthy tissues in prostate cancer xenograft model
- Initial ATNM-400 preclinical data to be presented at AACR ...
Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Thursday, 27th March at 8:45 am
- 99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models
- ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in healthy tissues in prostate cancer xenograft model
- Initial ATNM-400 preclinical data to be presented at AACR ...
$Actinium (ATNM.US)$ The update featured the unveiling of ATNM-400, Actinium's new Actinium-225 (Ac-225) solid tumor program, which is a novel, non-PSMA targeting, first-in-class radiotherapy for prostate cancer. Initial preclinical data from ATNM-400 will be presented at AACR on April 27, 2025.
$Actinium (ATNM.US)$ Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today
PR Newswire· 5 mins ago
- Company to highlight recent significant progress made with its Actimab-A and Iomab-ACT clinical programs, leading-edge R&D and radiopharmaceutical manufacturing infrastructure
- Revitalized clinical programs focused on 3 separate multi-billion-dollar market opportunities in
myeloid malignancies, solid tumors and cell & gene therapy conditioning with clinical data ...
PR Newswire· 5 mins ago
- Company to highlight recent significant progress made with its Actimab-A and Iomab-ACT clinical programs, leading-edge R&D and radiopharmaceutical manufacturing infrastructure
- Revitalized clinical programs focused on 3 separate multi-billion-dollar market opportunities in
myeloid malignancies, solid tumors and cell & gene therapy conditioning with clinical data ...
1
$Actinium (ATNM.US)$
Major Breakthrough: Actinium Locks Critical Supply Deal for Revolutionary Cancer Treatment Development
Major Breakthrough: Actinium Locks Critical Supply Deal for Revolutionary Cancer Treatment Development
$Actinium (ATNM.US)$
Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities
Monday, 24th March at 4:15 pm
NEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler. Under this agreemen...
Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities
Monday, 24th March at 4:15 pm
NEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler. Under this agreemen...
1
No comment yet
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
toddfather69 : idk why you do this but im glad you do!!! THANK YOU VERY MUCH!!!
Jaguar8 OP toddfather69 : It became a habit already for me
CloverJen : thank you
HumbLearner : Huge sale order. Price gonna drop?![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
RIVERSIDE-007 : Thank you, Sir
View more comments...